




**CORRECTION**

# Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors

Georges Gebrael , Nicolas Sayegh , Vinay Mathew Thomas, Beverly Chigarira, Nishita Tripathi, Yeon Jung Jo, Haoran Li, Kamal Kant Sahu, Ayana Srivastava, Taylor McFarland, Benjamin L. Maughan, Umang Swami and Neeraj Agarwal 

© The Author(s), under exclusive licence to Springer Nature Limited 2023

*Prostate Cancer and Prostatic Diseases* (2024) 27:357; <https://doi.org/10.1038/s41391-023-00706-x>

Correction to: *Prostate Cancer and Prostatic Diseases* <https://doi.org/10.1038/s41391-023-00696-w>, published online 17 July 2023

In this article the author name Srivastava was incorrectly written as Strivastava.

The following sentence

Of these 205 patients, 146 individuals received ADT intensification with ARPIs, while 59 received ADT intensification with docetaxel.

should read

Of these 205 patients, 149 individuals received ADT intensification with ARPIs, while 56 received ADT intensification with docetaxel.